Hyperglycosylated human coagulation factor IX
- Application ID: EP14164727
- Status: █ APPLICATION WITHDRAWN
This EP application has the IPC combination A61 (MEDICAL OR VETERINARY SCIENCE; HYGIENE) and C12 (BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING). Novo Nordisk A/S is specialized in the combination A61 and C12. We found, that Coller IP Management Ltd, TransMIT GmbH, Kailuweit & Uhlemann, Lederer Keller Patentanwälte Partnerschaft mbB, Vossius & Partner Patentanwälte Rechtsanwälte mbB and 183 others are specialized in all of these IPC classes as well. For a similar patent, they might be a good choice.